Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase Zacks - Tue Jul 27, 11:38AM CDT

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 63.62 (-12.38%)
RGEN : 226.38 (+9.89%)
CORT : 20.02 (-0.60%)
NBRV : 1.0800 (-2.70%)
Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F Business Wire - Wed Jun 30, 10:58PM CDT

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that its Annual Report on Form...

RDY : 63.62 (-12.38%)
Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market Business Wire - Tue Jun 22, 1:07AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Icosapent Ethyl Capsules,...

RDY : 63.62 (-12.38%)
Global Response Aid Reports Midyear Sales Results for COVID Drug PR Newswire - PRF - Thu Jun 3, 9:00AM CDT

, UAE, /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several...

RDY : 63.62 (-12.38%)
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase Zacks - Mon May 17, 11:17AM CDT

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

RDY : 63.62 (-12.38%)
ADPT : 35.42 (-3.80%)
ADVM : 2.32 (-4.53%)
MIST : 5.45 (-1.27%)
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market BusinessWire - Tue May 11, 11:56PM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Ertapenem for Injection,...

RDY : 63.62 (-12.38%)
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 Zacks - Thu Apr 29, 11:00AM CDT

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA : 8.92 (-0.22%)
RDY : 63.62 (-12.38%)
AMRN : 4.00 (+1.52%)
CDMO : 24.95 (-0.56%)
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market BusinessWire - Thu Apr 29, 9:41AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Albendazole Tablets,...

RDY : 63.62 (-12.38%)
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India BusinessWire - Tue Apr 13, 1:03AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller General of India (DCGI) to import the...

RDY : 63.62 (-12.38%)
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market BusinessWire - Wed Apr 7, 3:56AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Sapropterin Dihydrochloride...

RDY : 63.62 (-12.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ACCESSWIRE - Tue Mar 9, 10:54PM CST

NEW YORK, NY / ACCESSWIRE / March 9, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 63.62 (-12.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY Newsfile Corp - Sun Mar 7, 4:41PM CST

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY). Such...

RDY : 63.62 (-12.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire - PRF - Wed Mar 3, 2:00AM CST

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 63.62 (-12.38%)
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid Zacks - Fri Feb 26, 8:47AM CST

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA : 8.92 (-0.22%)
RDY : 63.62 (-12.38%)
AMRN : 4.00 (+1.52%)
SAVA : 127.50 (+6.26%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY Newsfile Corp - Mon Feb 22, 12:17PM CST

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY)....

RDY : 63.62 (-12.38%)
Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market BusinessWire - Mon Feb 22, 12:13AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Lansoprazole DR Orally...

RDY : 63.62 (-12.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ACCESSWIRE - Sat Feb 20, 5:45PM CST

NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 63.62 (-12.38%)
Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V BusinessWire - Fri Feb 19, 4:45AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has initiated the process...

RDY : 63.62 (-12.38%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire - PRF - Thu Feb 18, 11:35PM CST

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 63.62 (-12.38%)
Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market BusinessWire - Thu Feb 18, 12:50AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fluphenazine Hydrochloride...

RDY : 63.62 (-12.38%)
Please wait...

Barchart Exclusives

Rising Energy Prices Increase Production Costs - This Week In Metals Barchart - Tue Jul 27, 10:14AM CDT
This week we look at China's efforts to keep a lid on metals prices and how rising energy prices are making it more expensive to mine and refine the metals that are the building blocks for infrastructure building and rebuilding. Q2 earnings for Steel Dynamics and Nucor exceeded expectations. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot